沙库巴曲缬沙坦对比奥美沙坦对原发性高血压患者心血管重构的影响:随机双盲活性对照研究
本研究为随机、多中心、双盲、双模拟、活性对照、平行组研究,纳入114例高血压且脉压升高的患者,比较沙库巴曲缬沙坦与奥美沙坦对心血管重构的影响。结果显示,沙库巴曲缬沙坦组左心室质量指数从基线至12周和52周的下降幅度均大于奥美沙坦组,且中心脉压降低更显著,但局部主动脉扩张性变化无显著差异。
要点
- 沙库巴曲缬沙坦较奥美沙坦更显著降低左心室质量指数,12周和52周差异均显著。
- 左心室质量指数下降在调整随访收缩压后仍显著,提示部分独立于降压效应。
- 沙库巴曲缬沙坦组中心脉压降低幅度显著大于奥美沙坦组。
核心结论
- 沙库巴曲缬沙坦相比奥美沙坦能更显著降低高血压患者的左心室质量指数,且中心脉压降低更明显。
- 左心室质量指数下降可能部分独立于收缩压降低,提示双作用机制可能超越单纯降压效应。
研究设计与样本
- 随机、多中心、双盲、双模拟、活性对照、平行组研究,共纳入114例高血压伴脉压升高的患者,每组57例。
- 采用磁共振成像评估基线和治疗12周、52周时的左心室质量和局部主动脉扩张性,并使用SphymoCor® XCEL设备测定中心脉搏压和收缩压。
主要发现
- 左心室质量指数从基线至12周的变化:沙库巴曲缬沙坦组-6.36 g/m2 vs 奥美沙坦组-2.32 g/m2,P=0.039。
- 左心室质量指数从基线至52周的变化:沙库巴曲缬沙坦组-6.83 g/m2 vs 奥美沙坦组-3.55 g/m2,P=0.029。
- 调整随访收缩压后,12周和52周的组间差异仍显著(P=0.036和P=0.019);调整收缩压变化后差异未达显著(P=0.0612和P=0.0529)。
- 两组间局部主动脉扩张性从基线至12周或52周的变化无显著差异。
- 沙库巴曲缬沙坦组中心脉压降低幅度大于奥美沙坦组(P=0.010)。
临床怎么用
- 对于高血压伴脉压升高且关注左心室肥厚逆转的患者,沙库巴曲缬沙坦可能提供优于奥美沙坦的左心室质量指数改善。
- 沙库巴曲缬沙坦对中心脉压的降低作用可能有助于减轻主动脉僵硬度相关的心血管风险。
局限性
- 样本量较小(共114例),可能影响统计效能和结果外推。
- 调整收缩压变化后左心室质量指数差异未达统计学显著,提示部分效应可能仍与降压相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-action angiotensin receptor blocker (ARB), and neprilysin inhibitor, on arterial stiffness and LV remodelling have not been investigated. METHODS AND RESULTS: This was a randomized, multi-centre, double-blind, double-dummy, active-controlled, parallel group, study to compare the effects on cardiovascular remodelling of sacubitril/valsartan with those of olmesartan in patients with hypertension and elevated pulse pressure. Magnetic resonance imaging scans were used to assess LV mass and local aortic distensibility, at baseline and at 12 and 52 weeks after initiation of treatment. Central pulse and systolic pressure were determined using a SphymoCor® XCEL device at each time point. A total of 114 patients were included, with 57 in each treatment group. The mean age was 59.8 years, and 67.5% were male. Demographic characteristics did not vary between the two sets of patients. Left ventricular mass index decreased to a greater extent in the sacubitril/valsartan group compared to the olmesartan group from baseline to 12 weeks (-6.36 vs. -2.32 g/m2; P = 0.039) and from baseline to 52 weeks (-6.83 vs. -3.55 g/m2; P = 0.029). These differences remained significant after adjustment for systolic blood pressure (SBP) at follow-up (P = 0.036 and 0.019 at 12 and 52 weeks, respectively) and similar signals (though formally non-significant) were observed after adjusting for changes in SBP (P = 0.0612 and P = 0.0529, respectively). There were no significant differences in local distensibility changes from baseline to 12 or 52 weeks between the two groups; however, there was a larger reduction in central pulse pressure for the sacubitril/valsartan group compared to the olmesartan group (P = 0.010). CONCLUSION: Since LV mass change correlates with cardiovascular prognosis, the greater reductions in LV mass indicate valuable advantages of sacubitril/valsartan compared to olmesartan. The finding that LV mass index decrease might be to some extent independent of SBP suggests that the effect of the dual-acting agent may go beyond those due to its BP-lowering ability.
引用
- Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017. PMID: 29029087. doi:10.1093/eurheartj/ehx525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。